US FDA accepts Dupixent for priority review in adults with prurigo nodularis
If approved, Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the US
Author
Britain’s GSK to buy Affinivax for up to $3.3 billion in vaccines push
GSK, the world’s largest vaccine maker by sales, has been under pressure to shore up its pipeline
BDR Pharma partners with Varenyam Healthcare to launch Sugmadex in India
Sugmadex is a pioneer in anaesthesia drugs offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular…
Sun Pharma acquires Uractiv portfolio from Fiterman Pharma in Romania
Financial terms of the transaction are confidential
US FDA approves Roche’s Evrysdi for use in babies under two months with Spinal Muscular Atrophy
Approval based on interim Rainbowfish data which show pre-symptomatic babies treated with Evrysdi for at least one year were able…
UK and Sweden sign MoU to co-operate in lifesciences
The purpose of the MoU is to promote co-operation among the participants across local, regional and national healthcare, research…
US FDA approves Novartis Kymriah CAR-T cell therapy for adult patients with relapsed or refractory…
68 per cent of patients receiving Kymriah in the Elara trial experienced complete response, with an 86 per cent overall response…
DFE Pharma opens Centre of Excellence in India to provide fast-track formulation services
The new ‘Closer to the Formulator’ (C2F) centre offers DFE Pharma’s excipient expertise to help pharma companies achieve…
JB Chemicals and Pharma announces new identity
The company announced its new identity at a media conference organised last week in Mumbai
Venus Remedies registers 9.22 per cent growth in annual sales for FY 21-22
The company’s annual sales grew from Rs 548.12 crores in FY 2020-21 to Rs 598.65 crores this fiscal